Photo taken from elevate.in
Jul 5, 2024, 14:21
Rugengamanzi Eulade: Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era
Rugengamanzi Eulade, Oncologist at
“We have published:
‘A comparison of clinical profile and treatment outcome of Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era’ in BMC Cancer.
Highlights
- The 2-year OS rate for HIV-HL was 34%, while that for non-HIV-HL was 67%.
Among the HIV-HL patients, predictors of a poorer outcome were a CD4 count ≤ 200 cells/mm3 (P = 0.05), lack of HAART use (P = 0.00), and the use of HAART for ≤ 10 months (P = 0.00).
Conclusion: HIV positivity is still a poor prognostic factor.”
Additional information.
Source: Rugengamanzi Eulade/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 22:22
Nov 18, 2024, 22:02
Nov 18, 2024, 21:55
Nov 18, 2024, 20:54
Nov 18, 2024, 18:36
Nov 18, 2024, 18:32